Teplizumab
Generic name: Teplizumab
Brand names: Tzield
Dosage form: intravenous solution (mzwv 2 mg/2 mL)
Drug class:
Miscellaneous antidiabetic agents
Usage of Teplizumab
Teplizumab is used to delay the onset of stage 3 type 1 diabetes in people at least 8 years old with stage 2 type 1 diabetes.
Teplizumab may also be used for purposes not listed in this medication guide.
Teplizumab side effects
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Tell your medical caregivers if you have signs of cytokine release syndrome (CRS), a serious side effect: fever, chills, trouble breathing, confusion, severe vomiting or diarrhea, fast or irregular heartbeats, feeling light-headed or very tired.
Teplizumab may cause serious side effects. Call your doctor at once if you have:
Common side effects of teplizumab may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before taking Teplizumab
Tell your doctor if you have:
May harm an unborn baby. Do not use if you are pregnant and for at least 30 days before a planned pregnancy. Tell your doctor if you become pregnant.
You should contact the Adverse Event reporting line at 1-844-778-2246 if exposed to teplizumab during pregnancy.
Do not breastfeed while using teplizumab. If you are considering breastfeeding, use a breast pump and throw out any milk you collect during treatment with this drug and for at least 20 days after your last dose.
Relate drugs
How to use Teplizumab
Usual Adult Dose for Diabetes Type 1:
Usual dose: Body surface area-based dosing by intravenous infusion once dailyDosing:-Day 1: 65 mcg/m2-Day 2: 125 mcg/m2-Day 3: 250 mcg/m2-Day 4: 500 mcg/m2-Days 5 through 14: 1,030 mcg/m2Duration of therapy: 14 daysComments:-Confirm the presence of Stage 2 type 1 diabetes by documenting at least two positive pancreatic islet cell autoantibodies and state of dysglycemia without overt hyperglycemia using an oral glucose tolerance test (OGTT); an alternate test may be used if OGTT is not available.-Patients should not have type 2 diabetes.-Complete blood count and liver enzyme tests should be done before initiating the treatment.-This drug is not recommended in patients with:---Lymphocyte count less than 1,000 lymphocytes/mcL---Hemoglobin less than 10 g/dL or Platelet count less than 150,000 platelets/mcL---Absolute Neutrophil count less than 1,500 neutrophils/mcL---Elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 2 times the upper limit of normal (ULN) or bilirubin greater than 1.5 times ULN---Laboratory or clinical evidence of acute infection with Epstein-Barr virus (EBV) or cytomegalovirus (CMV)---Active serious infection or chronic active infection other than localized skin infections-All age-appropriate vaccination should be completed before initiating the treatment.-Administer premedication before every dosing for the first 5 days with:---A nonsteroidal anti-inflammatory drug (NSAID) or acetaminophen---An antihistamine and/or an antiemetic-If a dose is missed, resume the administration of remaining doses based on 14-day dosing schedule.-Do not administer this drug twice on the same day.Use: To delay the onset of Stage 3 type 1 diabetes in patients of 8 years or older
Warnings
Tell your medical caregivers if you have symptoms of a serious side effect, such as fever, chills, trouble breathing, vomiting, or severe tiredness.
Call your doctor at once if you have fever, chills, sore throat, body aches, tiredness.
Also call your doctor at once if you have stomach pain (upper right side), itching, dark urine, or jaundice (yellowing of the skin or eyes).
What other drugs will affect Teplizumab
Other drugs may affect teplizumab, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions